Trial Profile
Safety and efficacy of Ofatumumab in Childhood-Onset Systemic Lupus Erythematosus in patients who are Rituximab-intolerant
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Nov 2018
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Therapeutic Use
- 20 Nov 2018 New trial record
- 24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting